The Indian Council of Medical Research (ICMR) has invited Expressions of Interest (EoI) from eligible organisations, companies, and manufacturers for the development and production of monoclonal antibodies (mAbs) against Nipah viral disease.
Nipah virus (NiV) has emerged as a major zoonotic threat in India, with repeated outbreaks recorded since 2001. Case fatality rates range between 40% and 75%, depending on the level of clinical care available. In India and Bangladesh, the circulating strain, the Bangladesh clade (NiV-B), is known for frequent person-to-pe
Continue Reading on The Hindu
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.